Compare LXU & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXU | GYRE |
|---|---|---|
| Founded | 1968 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.6M | 755.7M |
| IPO Year | 1969 | N/A |
| Metric | LXU | GYRE |
|---|---|---|
| Price | $9.52 | $8.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $10.25 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 524.2K | 77.0K |
| Earning Date | 02-25-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $585,065,000.00 | $107,265,000.00 |
| Revenue This Year | $16.97 | $11.59 |
| Revenue Next Year | $0.90 | $26.31 |
| P/E Ratio | ★ N/A | $201.83 |
| Revenue Growth | ★ 12.49 | 2.13 |
| 52 Week Low | $4.88 | $6.11 |
| 52 Week High | $10.17 | $13.75 |
| Indicator | LXU | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 57.06 |
| Support Level | $9.23 | $7.72 |
| Resistance Level | $10.17 | $8.38 |
| Average True Range (ATR) | 0.37 | 0.33 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 56.76 | 76.18 |
LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.